The Question

This is our most speculative prediction: will any person alive today reach 150 years old? Our model gives it 31% probability. Low — but not negligible. This is a forecast running to 2100 and beyond. The oldest verified human ever was Jeanne Calment of France, who died in 1997 at 122. Despite decades of research, nobody has beaten that record. Whether 150 is a hard biological wall or simply the current limit of what medicine can achieve is the question that billions of dollars of research money is now racing to answer.

Research laboratory focused on cellular biology

First, an important distinction. Average life expectancy has soared — from about 47 years in 1900 to roughly 80 today. But that came almost entirely from stopping people dying young: better sanitation, vaccines, antibiotics. The maximum human lifespan has barely moved. The new longevity research is betting on something different: not preventing early death, but actually slowing or reversing the biological process of ageing. Altos Labs — backed by over $3 billion including from Jeff Bezos — is pursuing cellular reprogramming: using proteins called Yamanaka factors to reset cells to a younger state. In mice, it works. The question is whether it can work safely in humans.

What the Evidence Shows

"Ageing is not inevitable in the same way that gravity is inevitable. It is a biological process, and biological processes can be intervened upon. The question is not whether we can slow ageing but whether we can do so safely, equitably, and fast enough to matter for people alive today."

— David Sinclair, Harvard Medical School, Lifespan: Why We Age and Why We Don't Have To (2023 Ed.)

David Sinclair at Harvard argues that ageing is essentially an information problem — cells gradually lose the ability to read their own genetic instructions correctly. His lab has shown that restoring NAD+, a molecule that helps proteins called sirtuins maintain cellular health, reverses some ageing markers in mice. You can buy NAD+ precursor supplements in any health food shop, and millions do. The human evidence is still thin — but serious scientists are paying attention, which wasn't true a decade ago.

The most rigorous human longevity trial currently running is called TAME — Targeting Aging with Metformin. Metformin is a cheap diabetes drug that has been around for 60 years. It appears to activate biological pathways linked to longer life in multiple animal species. TAME is testing whether a drug costing $4 a month can delay the onset of multiple age-related diseases simultaneously in healthy older adults. If it can, that is profound — and could open a regulatory pathway for treating ageing as a medical condition, something the FDA does not currently recognise.

"The oldest verified human lived to 122. Getting to 150 would require breaking biology in ways we have never managed — so far."

Then there are the blue zones — communities where people already live unusually long, healthy lives: Sardinia, Okinawa, Loma Linda, Nicoya, Ikaria. What researchers found was not a secret supplement. It was mostly plant-based food, daily movement woven into ordinary life, strong social bonds, and a sense of purpose. None of these populations had access to cutting-edge longevity drugs. That is worth sitting with.

Why This Is Happening

Healthspan matters as much as lifespan. Most serious longevity researchers are not trying to extend nursing home years to 150. They want to compress decline — keep people genuinely healthy for longer and shrink the final deterioration window. Bryan Johnson, who reportedly spends $2 million a year on his "Blueprint" protocol, is chasing this goal. Some of his interventions are well-supported by science. The full system is untested.

The social implications are underexplored. If radical life extension works, who gets it? Expensive treatments make living to 150 a privilege of the wealthy — entrenching today's inequalities not for decades but centuries. Pension systems, inheritance structures, career paths, relationships — all would need rethinking. These are not science fiction questions. They are policy planning questions, and nobody is planning.

The regulatory path doesn't yet exist. The FDA does not recognise ageing as a disease, so there is no approved route for a drug that treats ageing itself rather than a specific condition. TAME is trying to create one — by demonstrating that delaying the whole cluster of age-related diseases at once is effectively the same thing as treating ageing. If it works, it opens a door that is currently locked.

What Could Happen

By 2100: First Person Reaches 150 — The Main Prediction Possible · 31%

Cellular reprogramming — or a successor technology — achieves safe, partial biological age reversal in humans by the 2040s. Combined with senolytics (drugs that clear out damaged "zombie" cells), NAD+ restoration, and rapamycin analogues, the maximum human lifespan extends past 130 by mid-century and reaches 150 before 2100. The first verified 150-year-old is likely a child alive today in a high-income country who has access to the full stack of longevity interventions as they develop.

By 2060: Healthspan to 95–100 On Average, Max Lifespan Below 135 Most likely · 55%

Metformin, rapamycin analogues, senolytics, and lifestyle optimisation extend healthy middle age and shrink the period of decline. Average life expectancy in wealthy countries rises to 90–95 by 2060. The maximum lifespan ceiling shifts modestly to perhaps 130–135. Reaching 150 remains out of reach. Longevity medicine becomes a real clinical specialty — but not the transformation of human life that the field's most ambitious researchers are betting on.

By 2100: Biological Ceiling Confirmed, Maximum Lifespan Below 130 Less likely · 14%

The first generation of intensive longevity interventions delivers real but limited results, with maximum lifespan remaining stubbornly below 130. Cellular reprogramming in humans proves riskier than animal models suggested — cancer risks that are difficult to eliminate. The biological ceiling turns out to be harder than the longevity field assumed. The field pivots to quality of later life rather than quantity of years. Valuable — but not what the billions were betting on.

The Forecast The World Verdict
We assign 31% probability that a person alive today will live to 150 years old — a long-horizon prediction extending to 2100, and deliberately a low-confidence one. The science is more serious than most people appreciate. Altos Labs, David Sinclair's lab at Harvard, and the TAME trial represent genuine scientific inquiry, not wellness marketing. The 69% probability that no one currently alive reaches 150 reflects the biological obstacles: the complexity of multi-system ageing, the difficulty of translating animal results to humans, and the sobering fact that despite decades of serious effort, no one has extended maximum human lifespan beyond Jeanne Calment's record of 122. The most likely outcome is not radical longevity but a radical improvement in healthspan — people living to 90 or 95 in genuinely good health rather than medically managed decline. Enormously valuable. But not the same as 150. The ethical questions radical longevity raises — about access, inheritance, meaning, pension systems — deserve public attention now, before the science forces them upon us.

What Can We Do

Active elderly people in a blue zone community

If you want to improve your own odds today, the evidence strongly favours low-tech over cutting-edge. Regular aerobic exercise is the single most robustly proven longevity intervention that exists. 150 minutes a week of moderate effort — a brisk walk, a swim, a bike ride — improves cardiovascular health, cognitive function, and muscle mass. No supplement on the market matches that effect. Sleep is the second most powerful lever: seven to nine hours a night is linked to better outcomes across virtually every age-related disease. Not exciting answers. But honest ones.

The blue zone research points toward something molecular biology can miss: social connection is as powerful a predictor of longevity as most biomarkers. Belonging to a community, having a reason to get up in the morning — the Japanese call it "ikigai" — appears consistently in the data. No pill replicates it.

For policymakers, the social conversation the longevity field hasn't forced publicly can't wait. Pension systems built around life expectancy of 80 are already under pressure. A world where many people live to 100 requires rethinking work, retirement, and inheritance. The science is uncertain. The demographic trend is not.

Sources
  • Altos Labs Scientific Overview and Research Programme (2024)
  • Sinclair, D. et al.: Epigenetic Reprogramming and Ageing (Cell, 2023)
  • TAME Trial: Targeting Aging with Metformin — NIH Protocol (2024)
  • Buettner, D.: The Blue Zones — Lessons for Living Longer (2023 Ed.)
  • Hayflick, L.: The Limited In Vitro Lifetime of Human Diploid Strains (Exp. Cell Res., 1961)
  • Kaeberlein, M.: Rapamycin and Ageing — An Update (Nature Aging, 2024)